Chronic granulomatous disease (CGD) is a rare primary immunodeficiency due to an abnormal function of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase; NADPH oxidase is a key enzyme for the cellular "respiratory burst", the cellular process that converts molecular oxygen to the oxygen free-radical superoxide. As a consequence of NADPH oxidase defect, CGD patients suffer from recurrent life-threatening infections and from exceeding inflammatory responses leading to granulomas. This article analyzes clinical aspects of CGD. Furthermore, using the CGD model, we focused on the future perspective to reduce atherosclerosis and its complications.